ITMCTR2024000008
Recruiting
N/A
Clinical observation on the treatment of moderate female stress urinary incontinence with optimized formula of Qishi granules based on the theory of spleen kidney correlation
ConditionsFemale stress urinary incontinence
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Female stress urinary incontinence
- Sponsor
- Xiyuan Hospital, China Academy of Chinese Medical Sciences
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who meet the Western and Traditional Chinese Medicine diagnosis criteria for moderate SUI in women;
- •2\. Women aged between 18 and 70 years old;
- •3\. Not using any traditional Chinese or Western medicine for treating SUI in the past week;
Exclusion Criteria
- •1\. Urinary incontinence patients caused by neurogenic bladder, psychological urinary incontinence, urgent urinary incontinence, mixed urinary incontinence, urethral sphincter insufficiency requiring surgical treatment, ectopic ureter, uncontrolled urinary tract infection, etc;
- •2\. Those with serious cardiovascular diseases, liver diseases, kidney diseases, hematological diseases, lung diseases, or serious diseases that affect their survival, such as cancer or AIDS, which the researchers consider not suitable for inclusion. Liver function ALT, AST, kidney function BUN exceeding 50% of the upper limit of normal value, and kidney function Cr exceeding the upper limit of normal value will not be selected;
- •3\. Allergy. Duloxetin enteric coated capsules are prohibited for patients who are known to be allergic to any non active ingredients in Duloxetin enteric coated capsules or products;
- •4\. For patients who have previously used duloxetine enteric coated capsules and have shown poor efficacy
- •5\. Simultaneously using monoamine oxidase inhibitors. Prohibition of combination with monoamine oxidase inhibitors (MAOIs);
- •6\. Untreated narrow angle glaucoma. Clinical trials have shown that duloxetine increases the risk of pupil dilation, therefore, untreated narrow angle glaucoma patients should avoid using duloxetine;
- •7\. Those who do not meet the inclusion criteria, do not use medication according to regulations, cannot determine the efficacy, or have incomplete information that affects the efficacy judgment;
- •8\. Legally disabled patients (blind, deaf, mute, intellectually disabled), and mentally ill patients;
- •9\. Pregnant or lactating patients;
- •10\. Patients who have been determined by the researchers to be unable to cooperate in completing the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 1
Clinical Observation on Treating Moderate and Severe Ulcerative Colitis with Bupiwei Xieyinhuo Shengyang supplemented decoctiolcerative ColitisITMCTR2100005224Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Not Yet Recruiting
Phase 1
A clinical study on the treatment of generalized anxiety disorder with theITMCTR2000004129West China Hospital, Sichuan University
Recruiting
N/A
Investigation of clinical course and treatment of acute exacerbation of interstitial lung disease - A Prospective Observational StudyJPRN-UMIN000043154Hamamatsu University School of Medicine400
Recruiting
Phase 1
Clinical observation on the therapeutic effect of 'three-part acupoint combination' combined with Aili eye drops in the treatment of perimenopausal dry eye syndrome.dry eye diseaseITMCTR2000003938Shanghai General Hospital
Not Yet Recruiting
Phase 2
A research study for treatment of mild to moderate ulcerative colitis with ayurvedic drugs and comparison with Allopathic treatmentHealth Condition 1: K518- Other ulcerative colitisCTRI/2024/05/067117Dept of Shalya Tantra